The patho genesis of multiple sclerosis (MS) remains unknown. A lthough inflammation, demyelination and axonal injury are all involved, the primary patho genic process is not clear. In this paper we challenge the hypothesis that MS is a primary inflammatory condition, and suggest that axonal damage may occur independently.
Ferguson B , Matyszak MK , Esiri MM , Perry VH.Axonal damage in acute multiple sclerosis lesions . Brain1997; 120: 393-399 .
2.
Trapp BD , Peterson J , Ransohoff RM , Rudick R , Mörk S , Bö L.Axonal transection in the lesions of multiple sclerosis . N Engl J Med1998; 338: 278-285 .
3.
Bitsch A , Schuchardt J , Bunkowski S , Kuhlmann T , Brück W.Acute axonal injury in multiple sclerosis correlation with demyelination and inflammation . Brain2000; 123: 1174-1183 .
4.
De Stefano N , Narayanan S , Francis GS , Arnaoutelis R , Tartaglia MC , Antel JPet al.Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability . Arch Neurol2001; 58: 65-70 .
5.
Ingle GT , Stevenson VL , Miller DH , Thompson AJ.Primary progressive multiple sclerosis: a 5-year clinical and MR study . Brain2003; 126: 2528-2536 .
6.
Griffin CM , Dehmeshki J , Chard DT , Parker GJ , Barker GJ , Thompson AJet al.T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis . Mult Scler2002; 8: 211-216 .
7.
Brex PA , Leary SM , O’Riordan JI , Miszkiel KA , Plant GT , Thompson AJet al.Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis . J Neurol Neurosurg Psych2001; 70: 544-547 .
8.
Dalton CM , Brex PA , Jenkins R , Fox NC , Miszkiel KA , Crum WRet al.Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis . J Neurol Neurosurg Psych2002; 73: 141-147 .
9.
Rocca MA , Mezzapesa DM , Falini A , Ghezzi A , Martinelli V , Scotti Get al.Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis . Neuroimage2003; 18: 847-855 .
10.
Neumann H.The immunological microenvironment in the CNS: implications on neuronal cell death and survival . J Neural Transm2000; S59: 59-68 .
11.
Streit WJ , Graeber MB , Kreutzberg GW.Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system . J Neuroimmunol1989; 21: 117-123 .
12.
Moalem G , Leibowitz-Amit R , Yoles E , Mor F , Cohen IR , Schwartz M.Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy . Nature Med1999; 5: 49-55 .
13.
Serpe CJ , Sanders VM , Jones KJ.Kinetics of facial motor-neuron loss following facial nerve transection in severe combined immunodeficient mice . J Neurosci Res2000; 62: 273-278 .
14.
Rapalino O , Lazarov-Spiegler O , Agranov E , Velan GJ , Yoles E , Friadakis Met al.Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats . Nature Med1998; 4: 814-821 .
15.
Yan Q , Elliott J , Snider WD.Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death . Nature1992; 360: 753-755 .
16.
Gravel C , Götz R , Lorrain A , Sendtner M.Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons . Nature Med1997; 3: 765-769 .
17.
Ebers GC.Natural history of multiple sclerosis . J Neurol Neurosurg Psych2001; 71: II16-II19 .
18.
Confavreux C , Vukusic S , Moreau T , Adeleine P.Relapses and progression of disability in multiple sclerosis . N Engl J Med2000; 343: 1430-1438 .
19.
Kremenchutzky M , Cottrell D , Rice G , Hader W , Baskerville J , Koopman W , Ebers GC.The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation . Brain1999; 122: 1941-1950 .
20.
Thompson AJ , Kermode AG , Wicks D , MacManus DG , Kendall BE , Kingsley PEet al.Major differences in the dynamics of primary and secondary progressive multiple sclerosis . Ann Neurol1991; 29: 53-62 .
21.
de Jong BA , Schrijver HM , Huizinga TWJ , Bollen ELEM , Polman CH , Uitdehaag BMJet al.Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis . Ann Neurol2000; 48: 641-646 .
22.
The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology1993; 43: 655-661 .
23.
The Multiple Sclerosis Collaborative Research Group (MSCRG) . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol1996; 39: 285-294 .
24.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of inter-feron beta-1a in relapsing/remitting multiple sclerosis . Lancet1998; 352: 1498-1504 .
25.
The Copolymer 1 Multiple Sclerosis Study Group . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial . Neurology1995; 45: 1268-1276 .
26.
European Study Group on Interferon beta-1b in Secondary Progressive MS.Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet1998; 352: 1491-1497 .
27.
North American Study Group . Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomised controlled trial . American Academy of Neurology2000; (abstract).
28.
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results . Neurology2001; 56: 1496-1504 .
29.
Liu C , Blumhardt LD.Disability outcome measures in therapeutic trials of relapsing -remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts . J Neurol Neurosurg Psych2000; 68: 450-457 .
30.
Karlik S , Kirk S , Nicolle E , Kremenchutzky M , Rice GPA.Evidence for very long term efficacy of interferon beta 1b in relapsing remitting MS patients . Mult Scler Clin Lab Res2001; 7: S52-S52 .
31.
Rice GPA , Nicolle E , Lesaux J , Ebers GC , Kremenchutzky M , Karlik S.Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with interferon beta 1B . Mult Scler Clin Lab Res2001; 7: S54-S54 .
32.
Li DK , Paty DW.Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing -remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis . Ann Neurol1999; 46: 197-206 .
33.
European Study Group on Interferon beta-1b in Secondary Progressive Mutiple Sclerosis . The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis . Brain2000; 123: 2256-2263 .
34.
Comi G , Filippi M , Wolinsky JS.European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group . Ann Neurol2001; 49: 290-297 .
35.
Multiple Sclerosis Collaborative Research Group . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS . Neurology1999; 53: 1698-1704 .
36.
Parry A , Corkill R , Blamire A , Palace J , Narayanan S , Arnold Det al.Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis . J Neurol2003; 250: 171-178 .
37.
Moreau T , Coles A , Wing M , Thorpe J , Miller D , Moseley Iet al.CAMPATH-IH in multiple sclerosis . Mult Scler1996; 1: 357-365 .
38.
Coles AJ , Wing MG , Molyneux P , Paolillo A , Davie CM , Hale Get al.Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis . Ann Neurol1999; 46: 296-304 .
39.
Paolillo A , Coles AJ , Molyneux PD , Gawne-Cain M , MacManus D , Barker GJet al.Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H . Neurology1999; 53: 751-757 .
40.
Lucchinetti C , Brück W , Parisi J , Scheithauer B , Rodriguez M , Lassmann H.A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases . Brain1999; 122: 2279-2295 .
